Affimed NV
AFMD0.130USD
-0.004-2.99%
Cierre 05/14, 16:00（ET）Cotizaciones retrasadas 15 min
2.13MCap. mercado
PérdidaP/E TTM
Más Datos de Affimed NV Compañía
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Información de la empresa
Código de la empresaAFMD
Nombre de la empresaAffimed NV
Fecha de salida a bolsaSep 12, 2014
Fundada en2014
Director ejecutivoMr. Shawn M. Leland
Número de empleados76
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 12
DirecciónIm Neuenheimer Feld 582
CiudadHEIDELBERG
Bolsa de valoresNASDAQ Global Market Consolidated
PaísGermany
Código postal69120
Teléfono49621560030
Sitio Webhttps://www.affimed.com/
Código de la empresaAFMD
Fecha de salida a bolsaSep 12, 2014
Fundada en2014
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Wolfgang Fischer, Ph.D.
Dr. Wolfgang Fischer, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
145.54K
+34.45%
Ms. Denise Mueller
Ms. Denise Mueller
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
89.88K
+65.92%
Dr. Andreas Harstrick, M.D.
Dr. Andreas Harstrick, M.D.
Chief Medical Officer, Member of the Management Board
Chief Medical Officer, Member of the Management Board
76.04K
+88.54%
Dr. Mathieu Simon
Dr. Mathieu Simon
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
15.00K
+36.36%
Mr. Harry Welten
Mr. Harry Welten
Consulting Chief Financial Officer, Member of the Management Board
Consulting Chief Financial Officer, Member of the Management Board
15.00K
+36.36%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
14.00K
+16.67%
Ms. Uta Kemmerich-Keil
Ms. Uta Kemmerich-Keil
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
11.00K
+83.33%
Mr. Shawn M. Leland
Mr. Shawn M. Leland
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Bernhard R. M. Ehmer
Dr. Bernhard R. M. Ehmer
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Thomas Hecht, M.D.
Dr. Thomas Hecht, M.D.
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Wolfgang Fischer, Ph.D.
Dr. Wolfgang Fischer, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
145.54K
+34.45%
Ms. Denise Mueller
Ms. Denise Mueller
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
89.88K
+65.92%
Dr. Andreas Harstrick, M.D.
Dr. Andreas Harstrick, M.D.
Chief Medical Officer, Member of the Management Board
Chief Medical Officer, Member of the Management Board
76.04K
+88.54%
Dr. Mathieu Simon
Dr. Mathieu Simon
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
15.00K
+36.36%
Mr. Harry Welten
Mr. Harry Welten
Consulting Chief Financial Officer, Member of the Management Board
Consulting Chief Financial Officer, Member of the Management Board
15.00K
+36.36%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
14.00K
+16.67%
Desglose de ingresos
Divisa: EURHora de actualización: dom., 6 de abr
Divisa: EURHora de actualización: dom., 6 de abr
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioEUR
Nombre
Ganancia
Proporción
Collaboration revenue
155.00K
0.00%
Service revenue
0.00
0.00%
Por regiónEUR
Nombre
Ganancia
Proporción
United States
155.00K
100.00%
Germany
0.00
0.00%
Por negocio
Por región
Por negocioEUR
Nombre
Ganancia
Proporción
Collaboration revenue
155.00K
0.00%
Service revenue
0.00
0.00%
Accionista
Hora de actualización: mié., 14 de may
Hora de actualización: mié., 14 de may
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Gilde Healthcare Partners B.V.
5.34%
683 Capital Management LLC
4.30%
New Enterprise Associates (NEA)
2.91%
Point72 Asset Management, L.P.
2.25%
Hoess (Adi Ph.D.)
2.10%
Other
83.11%
Estadísticas de accionistas
Accionista
Proporción
Gilde Healthcare Partners B.V.
5.34%
683 Capital Management LLC
4.30%
New Enterprise Associates (NEA)
2.91%
Point72 Asset Management, L.P.
2.25%
Hoess (Adi Ph.D.)
2.10%
Other
83.11%
Tipo
Accionista
Proporción
Hedge Fund
8.99%
Venture Capital
8.49%
Individual Investor
6.01%
Investment Advisor/Hedge Fund
2.72%
Investment Advisor
1.62%
Research Firm
0.83%
Other
71.34%
Participación institucional
Hora de actualización: sáb., 22 de feb
Hora de actualización: sáb., 22 de feb
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
194
4.37M
28.73%
-2.85M
2024Q4
223
4.37M
28.70%
-3.86M
2024Q3
244
6.36M
129.59%
-2.88M
2024Q2
256
6.34M
129.44%
-2.70M
2024Q1
265
6.05M
127.57%
-3.49M
2023Q4
282
6.20M
128.84%
-3.49M
2023Q3
294
6.99M
46.94%
-2.84M
2023Q2
315
7.55M
50.71%
-3.53M
2023Q1
317
8.81M
59.15%
-2.41M
2022Q4
311
9.75M
66.09%
-701.23K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Gilde Healthcare Partners B.V.
812.50K
5.34%
+812.50K
--
Mar 15, 2024
683 Capital Management LLC
654.60K
4.3%
-270.00K
-29.20%
Dec 31, 2024
New Enterprise Associates (NEA)
442.65K
2.91%
--
--
Dec 31, 2024
Point72 Asset Management, L.P.
342.86K
2.25%
--
--
Dec 31, 2024
Hoess (Adi Ph.D.)
319.68K
2.1%
+66.08K
+26.06%
Mar 15, 2024
Tang Capital Management, LLC
148.31K
0.97%
--
--
Dec 31, 2024
Fischer (Wolfgang)
145.54K
0.96%
+37.29K
+34.45%
Mar 15, 2024
The Vanguard Group, Inc.
129.56K
0.85%
--
--
Dec 31, 2024
Intellectus Partners, LLC
126.41K
0.83%
+32.05K
+33.97%
Dec 31, 2024
Citadel Advisors LLC
114.77K
0.75%
+107.96K
+1.58K%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: mar., 6 de may
Hora de actualización: mar., 6 de may
Nombre
Proporción
Fidelity Enhanced Small Cap ETF
0%
SPDR S&P International Small Cap ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Invesco Nasdaq Biotechnology ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
iShares Biotechnology ETF
0%
Fidelity Enhanced Small Cap ETF
Proporción0%
SPDR S&P International Small Cap ETF
Proporción0%
ProShares Ultra Nasdaq Biotechnology
Proporción0%
Invesco Nasdaq Biotechnology ETF
Proporción0%
SPDR Portfolio Developed World ex-US ETF
Proporción0%
iShares Biotechnology ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Fecha
Tipo
Relación
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1